Previous 10 | Next 10 |
The following slide deck was published by Forty Seven, Inc. in conjunction with this Read more ...
-- 5F9 Well Tolerated with Clinical Activity as Monotherapy and in Combination with Azacitidine -- -- CR Rate of 55% and ORR of 100% Observed in Patients with Higher-Risk MDS -- -- CR/CRi Rate of 50% and ORR of 64% Observed in Patients with Untreated AML Who Are Ineligible for Inductio...
Oppenheimer's Mark Breidenbach says yesterday's 19% drop in Forty Seven ( FTSV ) was overdone. Shares plummeted on more than triple normal volume in response to an abstract that will be presented at the European Hematology Association Congress in Amsterdam June 13-16. More ne...
MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that updated data from its ongoing Phase 1b/2 clinical trial evaluating 5F9 i...
-- Forty Seven to Host Investor Event and Webcast on June 3, 2019 -- -- Forty Seven Management to Participate in MATTER Panel, The Current and Future Wave of Immuno-Oncology Therapies, on May 30, 2019 -- MENLO PARK, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinica...
Thinly traded Forty Seven ( FTSV -9.9% ) is down on average volume after posting Q1 results after the close yesterday. Since it has no product sales yet, upcoming events/catalysts merit mention. More news on: Forty Seven, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Forty Seven, Inc. (FTSV) Q1 2019 Earnings Conference Call May 13, 2019 4:30 PM ET Company Participants Hannah Deresiewicz – Stern Investor Relations Mark McCamish – Chief Executive Officer Chris Takimoto – Chief Medical Officer Ann Rhoads – Chief Fin...
Forty Seven (NASDAQ: FTSV ): Q1 GAAP EPS of -$0.74 misses by $0.08 . More news on: Forty Seven, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Updated Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in r/r NHL to be Presented at EHA and ICML in June -- – Updated Data from Phase 1b Trial of 5F9 as Monotherapy and in Combination with Azacitidine in AML and MDS to be Presented at ASCO and EHA in June...
-- Plan to evaluate Forty Seven’s CD47 antibody in combination with rituximab and Calquence (acalabrutinib) -- -- Novel combination aims to leverage the macrophage component of the innate immune system and a targeted kinase inhibitor -- MENLO PARK, Calif., May 10, 2019 (G...
News, Short Squeeze, Breakout and More Instantly...
The ongoing COVID-19 pandemic has caused significant disruptions to the global economy, as well as grievances for families witnessing their loved ones die from the virus. Fortunately, there's finally a light at the end of the tunnel as one investigative treatment has revealed potential efficacy ...
For years, Gilead Sciences ' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over ...
Shares of Forty Seven (NASDAQ: FTSV) climbed 64.5% in March, according to data from S&P Global Market Intelligence . The immuno-oncology specialist's stock skyrocketed early in the month after it was announced that the company was on track to be purchased by Gilead Sciences...